Clinical trial
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
NCT00003223 · SWOG Cancer Research Network, Other · Terminated
Key facts
| NCT number | NCT00003223 |
|---|---|
| Title | SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth |
| Official title | A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | fenretinide |
| Enrollment | 5 |
| Start date | Dec 1, 1997 |
| Primary completion | Mar 1, 2000 |
| Completion | Mar 1, 2000 |
| First posted | Sep 10, 2004 |
| Last update posted | Jul 24, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: